Renaissance Technologies - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 4 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Renaissance Technologies ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$70
-11.4%
59,700
+6.8%
0.00%
Q2 2023$79
-99.8%
55,900
+143.0%
0.00%
Q4 2020$40,000
-90.7%
23,000
-95.0%
0.00%
Q3 2020$432,000
+0.9%
460,806
-6.3%
0.00%
Q2 2020$428,000
+92.8%
491,700
+83.2%
0.00%
Q1 2020$222,000268,4000.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q4 2023
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$39,477,0003.01%
Raffles Associates 2,080,536$2,351,0002.51%
Defender Capital, LLC. 5,184,035$5,862,0002.30%
Prescott General Partners LLC 1,851,851$2,093,0000.16%
DAFNA Capital Management LLC 140,000$158,0000.04%
Fort Sheridan Advisors LLC 83,931$95,0000.03%
Long Focus Capital Management, LLC 215,000$243,0000.02%
XTX Topco Ltd 72,807$82,0000.02%
Ergoteles LLC 490,895$555,0000.02%
Beirne Wealth Consulting Services, LLC 45,000$51,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders